Literature DB >> 22267597

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.

Carlo Schneider1, Andreas Teufel, Tetyana Yevsa, Frank Staib, Anja Hohmeyer, Gudrun Walenda, Henning W Zimmermann, Mihael Vucur, Sebastian Huss, Nikolaus Gassler, Hermann E Wasmuth, Sergio A Lira, Lars Zender, Tom Luedde, Christian Trautwein, Frank Tacke.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a typical inflammation-associated cancer, but may also provoke antitumour immune responses whose significance and underlying mechanisms are incompletely understood.
OBJECTIVE: To characterise immune responses in the diethylnitrosamine (DEN)-liver cancer mouse model.
DESIGN: Tumour development and immune cell functions upon DEN treatment were compared between C57BL/6 wild-type (WT), chemokine scavenging receptor D6-deficient, B cell- (Igh6), CD4 T cell- (MHC-II) and T-/B cell-deficient (Rag1) mice. Relevance for human HCC was tested by comparing gene array results from 139 HCC tissues.
RESULTS: The induction of premalignant lesions after 24 weeks and of HCC-like tumours after 42 weeks by DEN in mice was accompanied by significant leucocyte infiltration in the liver and upregulation of distinct intrahepatic chemokines (CCL2, CCL5, CXCL9). Macrophages and CD8 (cytotoxic) T cells were most prominently enriched in tumour-bearing livers, similar to samples from human HCC. Myeloid-derived suppressor cells (MDSC) increased in extrahepatic compartments of DEN-treated mice (bone marrow, spleen). The contribution of immune cell subsets for DEN-induced hepatocarcinogenesis was functionally dissected. In D6(-/-) mice, which lack the chemokine scavenging receptor D6, hepatic macrophage infiltration was significantly increased, but tumour formation and progression did not differ from that of WT mice. In contrast, progression of hepatic tumours (numbers, diameters, tumour load) was strikingly enhanced in T-/B cell-deficient Rag1(-/-) mice upon DEN treatment. When mice deficient for B cells (Igh6(-/-), μMT) or major histocompatibility complex II were used, the data indicated that T cells prevent initial tumour formation, while B cells critically limit growth of established tumours. Accordingly, in tumour-bearing mice antibody production against liver-related model antigen was enhanced, indicating tumour-associated B cell activation. In agreement, T and B cell pathways were differentially regulated in gene array analyses from 139 human HCC tissues and significantly associated with patients' survival.
CONCLUSIONS: Distinct axes of the adaptive immune system, which are also prognostic in human HCC, actively suppress DEN-induced hepatocarcinogenesis by controlling tumour formation and progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267597      PMCID: PMC4533880          DOI: 10.1136/gutjnl-2011-301116

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  54 in total

1.  The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes.

Authors:  Karlin Raja Karlmark; Henning W Zimmermann; Christoph Roderburg; Nikolaus Gassler; Hermann E Wasmuth; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

2.  B cells and macrophages in cancer: yin and yang.

Authors:  Alberto Mantovani
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

3.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.

Authors:  Xingguang Liu; Zhenzhen Zhan; Dong Li; Li Xu; Feng Ma; Peng Zhang; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-03-27       Impact factor: 25.606

4.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

Authors:  Nicholas S Wilson; Becky Yang; Annie Yang; Stefanie Loeser; Scot Marsters; David Lawrence; Yun Li; Robert Pitti; Klara Totpal; Sharon Yee; Sarajane Ross; Jean-Michel Vernes; Yanmei Lu; Cam Adams; Rienk Offringa; Bob Kelley; Sarah Hymowitz; Dylan Daniel; Gloria Meng; Avi Ashkenazi
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

Review 5.  Immune responses in hepatocellular carcinoma.

Authors:  Firouzeh Korangy; Bastian Höchst; Michael P Manns; Tim F Greten
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

8.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

9.  A lymphotoxin-driven pathway to hepatocellular carcinoma.

Authors:  Johannes Haybaeck; Nicolas Zeller; Monika Julia Wolf; Achim Weber; Ulrich Wagner; Michael Odo Kurrer; Juliane Bremer; Giandomenica Iezzi; Rolf Graf; Pierre-Alain Clavien; Robert Thimme; Hubert Blum; Sergei A Nedospasov; Kurt Zatloukal; Muhammad Ramzan; Sandra Ciesek; Thomas Pietschmann; Patrice N Marche; Michael Karin; Manfred Kopf; Jeffrey L Browning; Adriano Aguzzi; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.

Authors:  Robert J B Nibbs; Derek S Gilchrist; Vicky King; Antonio Ferra; Steve Forrow; Keith D Hunter; Gerard J Graham
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

View more
  71 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

2.  Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.

Authors:  Sofia de Oliveira; Ruth A Houseright; Alyssa L Graves; Netta Golenberg; Benjamin G Korte; Veronika Miskolci; Anna Huttenlocher
Journal:  J Hepatol       Date:  2018-12-18       Impact factor: 25.083

3.  Loss of Dicer1 impairs hepatocyte survival and leads to chronic inflammation and progenitor cell activation.

Authors:  Xu-Feng Lu; Yong-Jie Zhou; Lei Zhang; Hong-Jie Ji; Li Li; Yu-Jun Shi; Hong Bu
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 4.  Liver macrophages in tissue homeostasis and disease.

Authors:  Oliver Krenkel; Frank Tacke
Journal:  Nat Rev Immunol       Date:  2017-03-20       Impact factor: 53.106

5.  The ABC of adaptive immunity in liver cancer.

Authors:  Tim F Greten
Journal:  Hepatology       Date:  2018-05-14       Impact factor: 17.425

6.  Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development.

Authors:  Ralf Weiskirchen; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

Review 7.  Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients.

Authors:  Matteo Donadon; Nina Cortese; Federica Marchesi; Matteo Cimino; Alberto Mantovani; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

8.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

Review 9.  Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.

Authors:  Nina Frey; Sascha Venturelli; Lars Zender; Michael Bitzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-29       Impact factor: 46.802

10.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Authors:  Guangfu Li; Dai Liu; Timothy K Cooper; Eric T Kimchi; Xiaoqiang Qi; Diego M Avella; Ningfei Li; Qing X Yang; Mark Kester; C Bart Rountree; Jussuf T Kaifi; David J Cole; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.